Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of rheumatoid arthritis
Patients must be either DMARD naive or have failed at least one DMARD agent (e.g. MTX, leflunamide or sulfasalazine)
Patients are allowed up to 3 DMARDs at study entry (e.g. MTX, sulfasalazine or hydroxychloroquine) as long as their dose was stable for 4 weeks prior to initiating study treatment
Disease activity at screening defined by ≥6 out of 28 tender joints and ≥6 out of 28 swollen joints and hsCRP \>10mg/L
You may not be if
Patients with severe rheumatoid arthritis (functional status class IV according to the ACR 1991 revised criteria)
Previous exposure to secukinumab or any other biologic, including TNF inhibitors.
Use of high potency opioid analgesics
Pregnant or nursing (lactating) women
Use of any investigational drug other than RA therapy and/or devices at the time of randomization or within 30 days or 5 half-lives of randomization, whichever is longer.
Clareo Health | A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
